Show simple item record

Immunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV.

dc.contributor.authorMackett, Mike
dc.contributor.authorCox, C
dc.contributor.authorPepper, Stuart D
dc.contributor.authorLees, Janice F
dc.contributor.authorNaylor, B A
dc.contributor.authorWedderburn, N
dc.contributor.authorArrand, John R
dc.date.accessioned2010-04-07T14:39:57Z
dc.date.available2010-04-07T14:39:57Z
dc.date.issued1996-11
dc.identifier.citationImmunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV. 1996, 50 (3):263-71 J. Med. Virol.en
dc.identifier.issn0146-6615
dc.identifier.pmid8923292
dc.identifier.doi10.1002/(SICI)1096-9071(199611)50:3<263::AID-JMV9>3.0.CO;2-7
dc.identifier.urihttp://hdl.handle.net/10541/95907
dc.description.abstractEpstein-Barr virus (EBV) is the cause of infectious mononucleosis and is associated with a variety of life-threatening diseases in humans. Therefore the development of an effective vaccine is an important objective. Many of the initial studies of vaccine efficacy analyse the ability of vaccine preparations to prevent the induction of lymphomas in cottontop tamarins by the B95-8 strain of EBV. We used a vaccinia virus recombinant expressing gp340, vMA1, tested previously in the cotton-top tamarin, to evaluate a common marmoset model in which the challenge virus, M81, resembles more closely the wild-type strains of EBV in the general population than does the standard B95-8 strain. We characterised the M81 strain of EBV with respect to the sequence of its gp340/220 gene and in regard to the presence of a region deleted in B95-8. Replication of the challenge virus in the group vaccinated with vMA1 was decreased when compared to control groups.
dc.language.isoenen
dc.subject.meshAmino Acid Sequence
dc.subject.meshAnimals
dc.subject.meshAntibodies, Viral
dc.subject.meshCallithrix
dc.subject.meshCell Line
dc.subject.meshDNA, Viral
dc.subject.meshDisease Models, Animal
dc.subject.meshFemale
dc.subject.meshFluorescent Antibody Technique, Indirect
dc.subject.meshGenetic Vectors
dc.subject.meshHerpesvirus 4, Human
dc.subject.meshImmunization
dc.subject.meshInfectious Mononucleosis
dc.subject.meshMale
dc.subject.meshMolecular Sequence Data
dc.subject.meshMouth Mucosa
dc.subject.meshVaccines, Synthetic
dc.subject.meshVaccinia virus
dc.subject.meshViral Matrix Proteins
dc.subject.meshViral Vaccines
dc.titleImmunisation of common marmosets with vaccinia virus expressing Epstein-Barr virus (EBV) gp340 and challenge with EBV.en
dc.typeArticleen
dc.contributor.departmentDepartment of Molecular Biology, Paterson Institute for Cancer Research, Christie Hospital NHS Trust, Withington, Manchester, England.en
dc.identifier.journalJournal of Medical Virologyen
html.description.abstractEpstein-Barr virus (EBV) is the cause of infectious mononucleosis and is associated with a variety of life-threatening diseases in humans. Therefore the development of an effective vaccine is an important objective. Many of the initial studies of vaccine efficacy analyse the ability of vaccine preparations to prevent the induction of lymphomas in cottontop tamarins by the B95-8 strain of EBV. We used a vaccinia virus recombinant expressing gp340, vMA1, tested previously in the cotton-top tamarin, to evaluate a common marmoset model in which the challenge virus, M81, resembles more closely the wild-type strains of EBV in the general population than does the standard B95-8 strain. We characterised the M81 strain of EBV with respect to the sequence of its gp340/220 gene and in regard to the presence of a region deleted in B95-8. Replication of the challenge virus in the group vaccinated with vMA1 was decreased when compared to control groups.


This item appears in the following Collection(s)

Show simple item record